Publications by authors named "Jordan L Whatley"
Article Synopsis
- Monovalent and bivalent COVID-19 vaccines containing the Omicron XBB.1.5 variant were approved for use during the 2023-2024 immunization season and are currently undergoing evaluation in a phase 2/3 study.
- Among participants who previously received previous vaccine doses, those who received the monovalent vaccine showed greater increases in neutralizing antibodies against various SARS-CoV-2 variants compared to those who received the bivalent vaccine.
- The results indicate that the XBB.1.5 mRNA vaccines generate strong immune responses against newer variants, validating the update of COVID-19 vaccines to include the XBB.1.5 spike protein.
Article Synopsis
- A phase 2/3 trial compared the safety and effectiveness of the new bivalent mRNA-1273.222 vaccine, targeting Omicron BA.4/BA.5 variants, against the original mRNA-1273 vaccine used as boosters in adults who had previously received it.
- Results showed that the bivalent vaccine produced stronger neutralizing antibody responses against the Omicron variants while maintaining similar effectiveness against the original virus compared to mRNA-1273.
- The safety profile for mRNA-1273.222 was consistent with the previous vaccine, with no new safety issues found, but further monitoring of vaccine effectiveness and potential new variants is advised.
